ClinicalTrials.gg
CompletedNCT04451954FBP00004Updated Sep 17, 2025

Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult Subjects

A Phase 1 interventional study of Quadrivalent RIV with H3 strain 1 and Quadrivalent RIV with H3 strain 1 and adjuvant in Influenza Immunisation and Healthy Volunteers, sponsored by Sanofi Pasteur, a Sanofi Company. Completed at 5 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-17.

Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 1, Interventional, and Prevention

From the registry’s dates

  • Primary completion was Sep 2021, 5 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 139 studies in Influenza, Human by Sanofi — 4 open to participants now, 6 under way, 1 of them phase 3. Influenza, Human · Sanofi.

Enrollment
79th of 126
210 · median 305
Started
2020
with 5 others
Phase 1
11 of 139
none open now
Registered
101st of 139
by date

Among the 139 studies in Influenza, Human by Sanofi, this one is the 79th largest by enrollment of the 126 interventional ones that give a count, is one of 6 that started in 2020, is one of 11 in phase 1, and was the 101st registered.

Influenza, Human

2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

4 of the 139 studies in Influenza, Human by Sanofi are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Influenza, Human by Sanofi, or all of them as a file.
02

Study summary

The primary objectives of the study are:

  • To describe the safety profile of the different formulations in all participants
  • To describe the hemagglutinin inhibition (HAI) and seroneutralization (SN) antibody responses against hemagglutinin (H1, H3, B/Victoria, and B/Yamagata) antigens present in the control vaccine in all groups at all timepoints.

The secondary objectives are:

  • To describe antigenic coverage in each group by assessing the HAI and SN antibody responses against a panel of H3 antigens (not present in any of the vaccine formulations).
  • To describe SN antibody responses in each group against each of the H3 antigens.
  • To compare H3 HAI and SN antibody responses for the groups with quadrivalent recombinant influenza vaccine (RIV) formulations with H3 antigens to those of the quadrivalent RIV control group.
  • To compare the HAI and SN antibody responses for the groups with quadrivalent RIV formulation with adjuvant to the group without adjuvant.
Read the detailed description

Study duration per participant is approximately 1 year

03

Conditions studied

  • Influenza Immunisation
  • Healthy Volunteers

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Older adults: Aged 50 years and older on the day of inclusion Young adults: Aged 18 to 30 years on the day of inclusion
  • form has been signed and dated
  • Able to attend all scheduled visits and to comply with all trial procedures

Exclusion criteria

Exclusion criteria:

  • Participant is pregnant, or lactating, or of and not using an effective method of or abstinence from at least 4 weeks prior to vaccination until at least 12 weeks postvaccination. To be considered of non-childbearing potential, a female must be premenarche, or for at least 1 year, or surgically sterile
  • Participation at the time of study enrollment (or in the 4 weeks preceding the study vaccination) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure
  • Receipt of any vaccine in the 4 weeks preceding the study vaccination or planned receipt of any vaccine in the 4 weeks following study vaccination
  • Previous vaccination against influenza during either of the previous 2 influenza seasons (2018-2019 and 2019-2020) with any licensed or influenza vaccine
  • Receipt of immune globulins, blood, or blood-derived products in the past 3 months
  • Known or suspected congenital or acquired immunodeficiency; therapy (such as anticancer chemotherapy or radiation therapy, within the preceding 6 months); or long-term systemic therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months) or receipt of hydroxychloroquine within the preceding 4 weeks
  • Dementia or any other cognitive condition at a stage that could interfere with following the trial procedures
  • Have known active or recently active (12 months) neoplastic disease or a history of any hematologic
  • History of influenza infection during either of the previous 2 influenza seasons (2018- 2019 or 2019-2020), confirmed by laboratory tests (including rapid tests) at that time
  • History of laboratory confirmed coronavirus disease 2019 (COVID-19), confirmed with a nucleic acid amplification test on a respiratory specimen, or known exposure to severe acute respiratory syndrome coronavirus (SARS-CoV-2) positive confirmed close contact (eg, family member, housemate, daycare provider, aged parent requiring care), in the 30 days preceding vaccination, at the discretion of the investigator
  • Self-reported or documented seropositivity for , , or
  • Known systemic to any of the vaccine components, or history of a life-threatening reaction to the vaccines used in the study or to a vaccine containing any of the same substances
  • Have any diagnosis, current or past, of an disease
  • Thrombocytopenia or bleeding disorder, contraindicating intramuscular vaccination based on investigator's judgment
  • Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily
  • Any change in chronic prescription medication or change in medication dose or dosage in the 60 days prior to enrollment
  • Alcohol abuse or substance abuse that, in the opinion of the investigator, might interfere with the study conduct or completion
  • Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion
  • Any current or past diagnosis of chronic pulmonary disease including asthma (history of childhood asthma is allowed), cystic fibrosis and chronic pulmonary obstructive disease
  • Have taken a high-dose inhaled corticosteroid within 6 months prior to study vaccination
  • of 40 or higher
  • Any current or past diagnosis of cardiac disease (eg, coronary artery disease, heart failure, or valvular heart disease [mild mitral valve prolapse allowed]). Participants with isolated primary (essential) hypertension are allowed
  • Moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (oral temperature ≥100.4 F [≥38.0 C]). A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided
  • Identified as an investigator or employee of the investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (ie, parent, spouse, natural or adopted child) of the investigator or employee with direct involvement in the proposed study
  • Personal or family history of Guillain-Barré syndrome
  • History of chronic kidney disease
  • Current or past diagnosis of thyroid disease (eg, thyroiditis [including Hashimoto's thyroiditis], hyperthyroidism, and hypothyroidism)

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
210 participants (actual)

Study arms

  • Experimental
    Group 1: Quadrivalent RIV with H3 strain 1, without adjuvant

    1 injection of quadrivalent RIV containing H3 strain 1, without adjuvant, in participants ≥ 50 years old

    Biological: Quadrivalent RIV with H3 strain 1

  • Experimental
    Group 2: Quadrivalent RIV with H3 strain 1, with adjuvant

    1 injection of quadrivalent RIV containing H3 strain 1, with adjuvant, in participants ≥ 50 years old

    Biological: Quadrivalent RIV with H3 strain 1 and adjuvant

  • Experimental
    Group 3: Quadrivalent RIV with H3 strain 2, without adjuvant

    1 injection of quadrivalent RIV containing H3 strain 2, without adjuvant, in participants ≥ 50 years old

    Biological: Quadrivalent RIV with H3 strain 2

  • Experimental
    Group 4: Quadrivalent RIV with H3 strain 2, with adjuvant

    1 injection of quadrivalent RIV containing H3 strain 2, with adjuvant, in participants ≥ 50 years old

    Biological: Quadrivalent RIV with H3 strain 2 and adjuvant

  • Active comparator
    Group 5: Quadrivalent RIV Control, without adjuvant

    1 injection of quadrivalent RIV containing 2018-19 Northern Hemisphere (NH) recommended H3 strain, without adjuvant, in participants ≥ 50 years old

    Biological: Quadrivalent RIV with 2018-2019 NH H3 strain

  • Active comparator
    Group 6: Quadrivalent RIV Control, with adjuvant

    1 injection of quadrivalent RIV containing 2018-19 NH recommended H3 strain, with adjuvant, in participants ≥ 50 years old

    Biological: Quadrivalent RIV with 2018-2019 NH H3 strain and adjuvant

  • Active comparator
    Group 7: Quadrivalent RIV Control, without adjuvant

    1 injection of quadrivalent RIV containing 2018-19 NH recommended H3 strain, without adjuvant, in participants 18-30 years old

    Biological: Quadrivalent RIV with 2018-2019 NH H3 strain

Interventions

  • BiologicalQuadrivalent RIV with H3 strain 1

    Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

  • BiologicalQuadrivalent RIV with H3 strain 1 and adjuvant

    Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

  • BiologicalQuadrivalent RIV with H3 strain 2

    Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

  • BiologicalQuadrivalent RIV with H3 strain 2 and adjuvant

    Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

  • BiologicalQuadrivalent RIV with 2018-2019 NH H3 strain

    Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

  • BiologicalQuadrivalent RIV with 2018-2019 NH H3 strain and adjuvant

    Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

06

What researchers measure

Primary outcomes

  1. Number of participants with immediate adverse events

    Immediate adverse events are unsolicited systemic adverse events reported in the 30 minutes after vaccination

    Time frame: Within 30 minutes after vaccination

  2. Number of participants with solicited injection site or systemic reactions

    Solicited injection site reactions: injection site pain, erythema, swelling, induration and bruising; solicited systemic reactions: fever, headache, malaise, and myalgia

    Time frame: From Day 0 to Day 7

  3. Number of participants with unsolicited adverse events

    Unsolicited (spontaneously reported) adverse events not not fulfilling criteria for solicited reactions

    Time frame: From Day 0 to Day 28

  4. Number of participants with serious adverse events

    Serious adverse events are collected throughout the study

    Time frame: From Day 0 to Day 365

  5. Number of participants with adverse events of special interest

    Adverse events of special interest are collected throughout the study

    Time frame: From Day 0 to Day 365

  6. Clinical safety laboratory test results

    Laboratory tests include complete blood count (CBC), platelet count, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, serum creatinine, serum lipase, and serum amylase)

    Time frame: From Day 0 to Day 7

  7. HAI and SN antibody titers against influenza antigens in the quadrivalent RIV control vaccine

    Influenza antibody titers are measured by HAI and SN assays

    Time frame: From Day 0 to Day 365

  8. Individual HAI and SN titers ratio against influenza antigens in the quadrivalent RIV control vaccine

    Titers ratio is calculated for the following time points: Day 7/Day 0, Day 28/Day 0, and Day 90/Day 0

    Time frame: From Day 0 to Day 90

  9. Number of participants with seroconversion to influenza antigens in the quadrivalent RIV control vaccine

    Seroconversion is defined as HAI antibody titer \< 10 \[1/dil\] at Day 0 and post-injection titer ≥ 40 \[1/dil\] at Day 28, or titer ≥ 10 \[1/dil\] at Day 0 and a ≥ 4-fold increase in titer \[1/dil\] at Day 28)

    Time frame: From Day 0 to Day 28

  10. HAI Ab titer ≥ 40 [1/dil]

    Influenza vaccine antibody titers are measured by HAI assay

    Time frame: From Day 0 to Day 365

  11. 2-fold and 4-fold increase in SN titers

    Influenza vaccine antibody titers are measured by SN assay

    Time frame: From Day 0 to Day 28

Secondary outcomes

  1. HAI antibody titers against influenza H3 antigens not present in the vaccine formulations and the SN antibody titers against each of the H3 antigens

    Influenza vaccine antibody titers are measured by HAI and SN assays

    Time frame: Day 0, Day 7, Day 28, Day 90, Day 180, and Day 365

  2. Individual HAI titer ratios against influenza H3 antigens not present in the vaccine formulations and individual SN titer ratio against each of the H3 antigens

    Titer ratio is calculated for the following time points: Day 7/Day 0, Day 28/Day 0, Day 90/Day 0

    Time frame: From Day 0 to Day 90

  3. Number of participants with seroconversion to influenza H3 antigens not present in the vaccine formulations

    Seroconversion is defined as HAI antibody titer \< 10 \[1/dil\] at Day 0 and post-injection titer ≥ 40 \[1/dil\] at Day 28, or titer ≥ 10 \[1/dil\] at Day 0 and a ≥ 4-fold increase in titer \[1/dil\] at Day 28)

    Time frame: Day 0 and Day 28

  4. 2-fold and 4-fold rise in SN antibody titers against each of the H3 antigens

    Influenza vaccine antibody titers a are measured by SN assay

    Time frame: Day 0, Day 7, Day 28, Day 90, Day 180, and Day 365

07

Study locations

5 sites
  • Investigational Site Number 8400003
    San Diego, California 92108, United States
  • Investigational Site Number 8400002
    Melbourne, Florida 32934, United States
  • Investigational Site Number 8400004
    Orlando, Florida 32806, United States
  • Investigational Site Number 8400001
    Peoria, Illinois 61614, United States
  • Investigational Site Number 8400005
    Rockville, Maryland 20850, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Sep 2021, 14 months.

Of 94 industry-sponsored phase 1 interventional studies under Influenza, Human, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 14 months is above that.

Counting every sponsor, half of 148 studies reached it within 11 months; a quarter within 4 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2020
First posted
Jun 30, 2020
StartActual
Jul 2, 2020
Primary completionActual
Sep 20, 2021
CompletionActual
Sep 20, 2021
Last update
Sep 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04451954
Responsible party
Sponsor
First posted
Jun 30, 2020
Start date
Jul 2, 2020
Primary completion
Sep 20, 2021
Completion
Sep 20, 2021
Last update
Sep 17, 2025

Study contacts

Clinical Sciences & Operations
study director · Sanofi Pasteur, a Sanofi Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion